T he concept that the immune system has a role in controlling cancer is not a recent one. More than a century ago, the surgeon William Coley hypothesized that postoperative bacterial infections could mobilize a patient's own resistance to tumour recurrence, and he developed a mixture of heat-killed bacteria for intratumoral injection that occasionally produced durable regressions 1 . More recently, the elucidation of molecular mechanisms underlying immune regulation has been instrumental in devising strategies to overcome cancer cells' ability to suppress the immune surveillance that would otherwise protect the host from tumour progression [2] [3] [4] . One approach to activating these antitumour immune responses has been termed 'checkpoint blockade' -referring to the use of antibodies that block immuneinhibitory pathways switched on by cancer cells. Five papers published in this issue [5] [6] [7] [8] [9] reveal a growing list of cancers that respond to checkpoint blockade and describe characteristics of those patients who respond to such therapies.
The immune checkpoints targeted by these therapies serve under normal conditions as molecular brakes, preventing hyperactivity of the T cells of the immune system and, in some cases, preventing autoimmunity 10 . CTLA-4 and PD-1 are two key cell-surface receptors that, when bound by their ligands, trigger such inhibitory pathways and dampen T-cell activity. In the case of the PD-1 pathway, expression of ligands such as PD-L1 on tumour cells can directly lead to the death of T cells expressing mammals of the Mesozoic era (which spans the Triassic, Jurassic and Cretaceous periods, from 252 million to 66 million years ago), it is second in size only to the earlier, carnivorous Repenomamus giganticus from China 2 . But Vintana was a herbivore. Among its specializations are high-crowned molariform teeth with multiple islets of enamel, good for grinding plant matter, and an expanded cheekbone to accommodate the attachment of large chewing muscles; the authors estimate that its bite force was twice that of a rodent of similar size. The animal also had relatively large eyes. This fact, in combination with adaptations of the part of the inner ear concerned with balance, suggests that Vintana may have been agile and fast.
Yet the skull also exhibits a few features characteristic of earlier relatives that seem to be the result of evolutionary reversals: the nose, palate and back of the skull contain bones generally thought to have been lost in the mammalian lineage before the common ancestor of living mammals. And its long, down-turned snout would have given it a distinctive appearance. It may be that Vintana looks remarkable to us owing to its evolution during Madagascar's long isolation, as Krause and colleagues propose, and indeed tooth wear suggests that it chewed differently from other gond wanatheres. But because we have no comparable cranial material of other gondwanatheres, it may also be that the entire group is similarly unusual.
However outlandish Vintana may look, incorporating its skull into phylogenetic analyses at last provides an idea of where gondwanatheres fit within Mammalia. It emerges that they share many characteristics with two groups of Mesozoic mammals now well known from the northern continents -multituberculates and haramiyids -which together comprise a group called Allotheria. Vintana is just the latest in an explosion of new discoveries, and controversies, relating to this group. Originally conceived of to unite taxa within the mammalian lineage on the basis of teeth with rows of cusps 3 , Allotheria was eventually redefined to include the relatively common multituberculate mammals and the thenmysterious haramiyids, which were known principally from isolated teeth 4 . Because the haramiyids were poorly known, the question of whether the grouping Allotheria reflects an evolutionary relationship has long been debated, so much so that the foremost reference work on Mesozoic mammals 5 has one chapter entitled ' Allotherians' and another denying that haramiyids were true mammals. Last year, two papers describing the first haramiyid skulls and skeletons and including them in new phylogenetic analyses arrived at competing hypotheses: one 6 . Last month, three new species of haramiyid were described, from near-complete specimens, with an analysis again favouring the existence of Allotheria and its placement within Mammalia 9 . Now, using a third set of characters, a somewhat different sampling of taxa and all the new information vouchsafed by Vintana, Krause and colleagues' model also supports the Allotheria grouping, the placement of Vintana within Allotheria, and an ancient origin for Mammalia.
Analyses of fossil taxa with no living descendants, of which Allotheria is an example, produce varying results that are subject to the choice of animals included, the characteristics considered and the type of analysis used. If the inclusion of Allotheria in Mammalia holds up, it may indeed prove to be that Pangaea's fragmentation contributed to mammalian diversification during the Mesozoic. This is not the same as the diversification of the mammalian groups we see today; Mesozoic mammals unrelated to modern marsupials and placentals swam like beavers, soared like flying squirrels and ate like foxes in the henhouse 10 PD-1. Furthermore, engagement of CTLA-4 or PD-1, which are expressed both on T cells and on other immune cells in an inflamed tumour microenvironment, can self-limit the antitumour response. Antibodies that block CTLA-4 (ipilimumab) and PD-1 (pembrolizumab and nivolumab) have been approved to treat patients, and the clinical responses are often durable, with some patients remaining free from disease progression for many years [11] [12] [13] . But until recently, little efficacy of these treatments has been noted beyond melanoma and renal-cell carcinoma. Furthermore, the precise cellular events triggered by antibody binding and their exact antigenic targets (the molecular structures to which the antibodies bind) remained unclear.
Powles et al. 5 (page 558) and Herbst et al.
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(page 563) present results from a phase I clinical trial of MPDL3280A, a monoclonal antibody that blocks the ligand PD-L1. Herbst and colleagues report that the antibody induces therapeutic responses in patients with nonsmall-cell lung cancer, melanoma, renal-cell carcinoma and other solid tumours -findings that support the known activity of other antibodies that block the PD-1-pathway in some of these diseases 11, [14] [15] [16] . Powles and colleagues analyse the effects of this antibody treatment in a larger group of patients with urothelial bladder cancer. Both clinical reports document durable responses in a subset of patients, and that the therapy has low toxicity, with only rare high-grade adverse events. These results substantially expand the spectrum of malignancies in which PD-1-pathway blockade has meaningful clinical activity.
Ever since the earliest reports of the effects of PD-1 blockade 14, 15, 17, 18 , PD-L1 expression by tumour cells has been a focus of studies looking for biomarkers that will predict a therapeutic response. Although it is clear that expression of PD-L1 on tumour cells makes it more likely that the patient will respond to PD1-pathway blockade, this is not a binary, static predictive marker. Herbst et al. and Tumeh et al. 7 (page 568) now reveal that it is not solely tumour-cell expression of PD-L1 that can enrich responses to PD-1-pathway blockade, but that expression of PD-L1 on immune cells infiltrating the tumour is also a key predictor of clinical activity (Fig. 1) . Tumeh et al. further show, using samples from patients with melanoma that were treated with pembrolizumab, that a certain set of conditions enables PD-1 blockade to mediate tumour regression. These are the presence of CD8 + T cells (a T-cell subset that directly kills its target cells) and immune cells that express PD-1 and PD-L1 at the tumour margin, together with a T-cell population with less-diverse antigen specificity. Taken together, the findings of these two papers suggest that tumours that have already been recognized by the immune system, and so contain infiltrating immune cells bearing PD-1 and PD-L1, are particularly sensitive to immune-checkpoint blockade.
The contributions from Yadav et al. 8 (page 572) and Gubin et al. 9 (page 577) add another dimension by suggesting that 'passenger' mutations -cancer-cell mutations that do not directly contribute to cancer initiation and progression -play a key part in tumour immunity. Although it is increasingly evident that the new antigens generated by such mutations are targeted by antitumour T cells, identifying which of these neo-antigens are functionally important has been a challenge. Yadav et al. sequenced the exomes (the protein-coding regions of the genome) of two mouse tumour-cell lines and compared these with the reference mouse exome to predict candidate neo-antigens in the tumour cells. In parallel, they identified which of the neo-antigens could potentially elicit immune responses by isolating those that bind to major histocompatibility complex (MHC) proteins, which present antigens to T cells, and then analysing the bound peptides by mass spectrometry.
Surprisingly, this process identified only a few candidate neo-antigens, but these were highly immunogenic in vivo (that is, they provoked a strong immune response) and were found to be encoded by genes that are unlikely to directly contribute to cancer development, confirming that changes in immunogenicity can result from passenger mutations (Fig. 1) . The approach presented in this report is a key advance for the discovery of immunogenic antigens and is applicable to many experimental systems. However, it remains to be seen whether the low numbers of neo-antigens discovered reflects an inherently limited sensitivity of the approach or whether the number of MHC-presented neo-antigens is indeed low.
A previous paper from the research group of Gubin et al. showed that a mutant spectrin-β2 protein was responsible for the strong immunogenicity of tumours in a particular mouse model 19 . Now, Gubin and colleagues find that tumours from the same model that become resistant to immune-mediated rejection have lost this neo-antigen. They go on to show that treatment with anti-PD-1 and/or anti-CTLA-4 antibodies enabled the mice to again reject these tumours. Using a similar approach to that of Yadav et al., the authors identify two mutations, in the Alg8 and Lama4 genes, that created neo-antigens mediating these effects. Vaccinating mice with these antigens induced tumour rejection at a level comparable to that of checkpoint-blockade therapy, convincingly demonstrating that tumour neo-antigens are potent functional targets of this therapy. This work also corroborates recent findings from another group 20 . These five papers, together with other recent studies, support the hypothesis that immune responses to tumour-specific mutations are central to both natural antitumour immunity and to the antitumour activity generated by checkpoint-blockade therapy. In another twist to the story, a paper 21 just published reports that, in patients with melanoma treated with ipilimumab, specific neo-antigens in the tumour are associated with a favourable clinical response. Intriguingly, these antigens bear a striking similarity to immunogenic antigens derived from bacteria and viruses, suggesting, perhaps, that Coley was on to something. ■
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M ost distance measurements in astronomy rely on bright sources of light with known power output. How bright an object looks in the sky depends on both its actual light output and its distance from an observer on Earth, so knowing the object's real and apparent brightness allows the distance to be determined. The type 1a supernovae used to discover that the Universe's expansion is accelerating are the best-known examples of such sources. However, a better method for estimating astronomical distances is to use simple geometry, and in this issue Hönig et al. 1 (page 528) demonstrate a new geometric-distance method.
If we know the length of the base of an isosceles triangle, with the two long (very long!) sides being the distance to an object, then we can solve for that distance given just one angle. Unfortunately, such a situation is rare in astronomy. The only well-used example is a star's parallax, in which the diameter of Earth's orbit is the base of the triangle and the angle is how much the star moves against the background stars as Earth moves from one side of its orbit around the Sun to the other every six months (Fig. 1) . A star that moves 1 arcsecond would be one 'parsec' away. Although the European Space Agency's Gaia satellite is taking parallax to a new level of micro-arcsecond precision, even it cannot use this geometricdistance method on anything distant enough to track the expansion of the Universe.
Quasars, and their less-luminous cousins the active galactic nuclei (AGNs), are objects powered by supermassive black holes that pull (accrete) matter towards them at high speeds. This accretion process releases enough kinetic energy as radiation for some of them to be bright enough to be seen across the Universe. But quasars and AGNs would seem to be unpromising prospects for applying geometric-distance measurements because almost all of the emission from these sources comes from a compact region that cannot be spatially resolved.
However, Hönig et al. show that there is a way to obtain the geometric distance to these objects. They invert the triangle used for parallax and put the base of the triangle at the AGN. The sizes of regions in the interior of AGNs are known from a technique called reverberation mapping. The central luminous source in an AGN is tiny, only a few tens of times larger than the supermassive black hole's event horizon -the boundary beyond which no radiation can escape. This source is unstable and varies quite rapidly. Imagine a single flash of light from this small source. This flash travels out at the speed of light. When, after some delay, it encounters gas or dust in its neighbourhood, that material lights up in response; in other words, it 'reverberates'. We can measure how far from the source the lit-up mater ial is just by 
